# Amrep Corp.: financial statements, quarterly

AXR · NYSE · CIK 6207 · [Real estate](/sectors/real-estate.md) · fiscal year ends Apr 30

Pages: [Overview](/companies/axr.md) · [Financials](/companies/axr/financials.md) · [Filings](/companies/axr/filings.md) · [Insiders](/companies/axr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/axr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [8.9](/filings/0001410578-24-002088.md) | [12.7](/filings/0001410578-25-000296.md) | [19.5 d](/filings/0001410578-25-001515.md) | [19.1](/filings/0001410578-25-001940.md) | [11.9](/filings/0001104659-25-120644.md) | [7.5](/filings/0001104659-26-027088.md) | [11.2 d](/filings/0001104659-26-086659.md) | [17.9](/filings/0001104659-26-107084.md) | [9.4](/filings/0001104659-25-120644.md) | [14.6](/filings/0001104659-26-027088.md) | [11.0 d](/filings/0001104659-26-086659.md) | [6.1](/filings/0001104659-26-107084.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [1.1](/filings/0001410578-24-002088.md) | [(0.1)](/filings/0001410578-25-000296.md) | [4.7 d](/filings/0001410578-25-001515.md) | [5.0](/filings/0001410578-25-001940.md) | [3.1](/filings/0001104659-25-120644.md) | [0.4](/filings/0001104659-26-027088.md) | [3.5 d](/filings/0001104659-26-086659.md) | [6.1](/filings/0001104659-26-107084.md) | [1.1](/filings/0001104659-25-120644.md) | [3.0](/filings/0001104659-26-027088.md) | [2.1 d](/filings/0001104659-26-086659.md) | [(0.2)](/filings/0001104659-26-107084.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.1](/filings/0001410578-24-002088.md) | [0.0](/filings/0001410578-25-000296.md) | [0.9 d](/filings/0001410578-25-001515.md) | [1.2](/filings/0001410578-25-001940.md) | [(0.3)](/filings/0001104659-25-120644.md) | [0.1](/filings/0001104659-26-027088.md) | [(0.0) d](/filings/0001104659-26-086659.md) | [1.9](/filings/0001104659-26-107084.md) | [0.4](/filings/0001104659-25-120644.md) | [0.3](/filings/0001104659-26-027088.md) | [1.3 d](/filings/0001104659-26-086659.md) | [0.0](/filings/0001104659-26-107084.md) |
| Net income | $m | [1.1](/filings/0001410578-24-002088.md) | [0.1](/filings/0001410578-25-000296.md) | [4.1 d](/filings/0001410578-25-001515.md) | [4.1](/filings/0001410578-25-001940.md) | [4.0](/filings/0001104659-25-120644.md) | [0.7](/filings/0001104659-26-027088.md) | [3.9 d](/filings/0001104659-26-086659.md) | [4.7](/filings/0001104659-26-107084.md) | [1.2](/filings/0001104659-25-120644.md) | [3.1](/filings/0001104659-26-027088.md) | [1.2 d](/filings/0001104659-26-086659.md) | [0.3](/filings/0001104659-26-107084.md) |
| Diluted EPS | $ per share | [0.21](/filings/0001410578-24-002088.md) | [0.02](/filings/0001410578-25-000296.md) | not reported | [0.76](/filings/0001410578-25-001940.md) | [0.75](/filings/0001104659-25-120644.md) | [0.13](/filings/0001104659-26-027088.md) | not reported | [0.87](/filings/0001104659-26-107084.md) | [0.22](/filings/0001104659-25-120644.md) | [0.58](/filings/0001104659-26-027088.md) | not reported | [0.05](/filings/0001104659-26-107084.md) |
| Basic EPS | $ per share | [0.21](/filings/0001410578-24-002088.md) | [0.02](/filings/0001410578-25-000296.md) | not reported | [0.77](/filings/0001410578-25-001940.md) | [0.76](/filings/0001104659-25-120644.md) | [0.13](/filings/0001104659-26-027088.md) | not reported | [0.88](/filings/0001104659-26-107084.md) | [0.22](/filings/0001104659-25-120644.md) | [0.59](/filings/0001104659-26-027088.md) | not reported | [0.05](/filings/0001104659-26-107084.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [16.7](/filings/0001410578-23-002624.md) | [18.0](/filings/0001410578-24-000162.md) | [29.7](/filings/0001410578-25-001515.md) | [40.4](/filings/0001410578-24-001588.md) | [40.1](/filings/0001410578-24-002088.md) | [36.9](/filings/0001410578-25-000296.md) | [39.5](/filings/0001104659-26-086659.md) | [48.9](/filings/0001410578-25-001940.md) | [44.6](/filings/0001104659-25-120644.md) | [50.0](/filings/0001104659-26-027088.md) | [52.3](/filings/0001104659-26-107084.md) | [48.7](/filings/0001104659-26-107084.md) |
| Total assets | $m | [118](/filings/0001410578-24-002088.md) | [119](/filings/0001410578-25-000296.md) | [123](/filings/0001410578-25-001515.md) | [127](/filings/0001410578-24-001588.md) | [129](/filings/0001410578-24-002088.md) | [129](/filings/0001410578-25-000296.md) | [134](/filings/0001104659-26-086659.md) | [141](/filings/0001410578-25-001940.md) | [140](/filings/0001104659-25-120644.md) | [144](/filings/0001104659-26-027088.md) | [145](/filings/0001104659-26-107084.md) | [146](/filings/0001104659-26-107084.md) |
| Total liabilities | $m | [4.2](/filings/0001410578-23-002624.md) | [5.2](/filings/0001410578-24-000162.md) | [4.8](/filings/0001410578-25-001515.md) | [4.8](/filings/0001410578-24-001588.md) | [4.0](/filings/0001410578-24-002088.md) | [3.0](/filings/0001410578-25-000296.md) | [3.8](/filings/0001104659-26-086659.md) | [5.9](/filings/0001410578-25-001940.md) | [4.1](/filings/0001104659-25-120644.md) | [4.6](/filings/0001104659-26-027088.md) | [4.1](/filings/0001104659-26-107084.md) | [4.5](/filings/0001104659-26-107084.md) |
| Long-term debt | $m | [0.0](/filings/0001410578-23-002624.md) | [0.0](/filings/0001410578-24-000162.md) | [0.0](/filings/0001410578-24-001102.md) | [0.0](/filings/0001410578-24-001588.md) | [0.0](/filings/0001410578-24-002088.md) | [0.0](/filings/0001410578-25-000296.md) | [0.0](/filings/0001410578-25-001515.md) | [0.0](/filings/0001410578-25-001940.md) | [0.0](/filings/0001104659-25-120644.md) | [0.0](/filings/0001104659-26-027088.md) | [0.0](/filings/0001104659-26-086659.md) | [0.0](/filings/0001104659-26-107084.md) |
| Shareholders' equity | $m | [114](/filings/0001410578-25-000296.md) | [114](/filings/0001410578-25-000296.md) | [118](/filings/0001104659-26-086659.md) | [122](/filings/0001104659-25-120644.md) | [125](/filings/0001104659-26-027088.md) | [126](/filings/0001104659-26-027088.md) | [130](/filings/0001104659-26-107084.md) | [135](/filings/0001104659-26-107084.md) | [136](/filings/0001104659-26-027088.md) | [139](/filings/0001104659-26-027088.md) | [141](/filings/0001104659-26-107084.md) | [141](/filings/0001104659-26-107084.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [0.0 d](/filings/0001410578-24-002088.md) | [1.5 d](/filings/0001410578-25-000296.md) | [7.3 d](/filings/0001410578-25-001515.md) | [10.7](/filings/0001410578-25-001940.md) | [(0.2) d](/filings/0001104659-25-120644.md) | [(3.2) d](/filings/0001104659-26-027088.md) | [3.0 d](/filings/0001104659-26-086659.md) | [9.5](/filings/0001104659-26-107084.md) | [(4.3) d](/filings/0001104659-25-120644.md) | [5.4 d](/filings/0001104659-26-027088.md) | [2.2 d](/filings/0001104659-26-086659.md) | [(3.6)](/filings/0001104659-26-107084.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001410578-24-002088.md) | [0.2 d](/filings/0001410578-25-000296.md) | [0.1 d](/filings/0001410578-25-001515.md) | [0.0](/filings/0001410578-25-001940.md) | [0.1 d](/filings/0001104659-25-120644.md) | [0.0 d](/filings/0001104659-26-027088.md) | [0.4 d](/filings/0001104659-26-086659.md) | [0.0](/filings/0001104659-26-107084.md) | [0.1 d](/filings/0001104659-25-120644.md) | [0.0 d](/filings/0001104659-26-027088.md) | [0.0 d](/filings/0001104659-26-086659.md) | [0.0](/filings/0001104659-26-107084.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q2 FY2023 (2022-10-31) | Q3 FY2023 (2023-01-31) | Q1 FY2024 (2023-07-31) | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [5,307](/filings/0001410578-23-002624.md) | [5,310](/filings/0001410578-24-000162.md) | [5,325](/filings/0001410578-24-001588.md) | [5,339](/filings/0001410578-24-002088.md) | [5,346](/filings/0001410578-25-000296.md) | [5,353](/filings/0001410578-25-001940.md) | [5,374](/filings/0001104659-25-120644.md) | [5,381](/filings/0001104659-26-027088.md) | [5,375](/filings/0001104659-26-107084.md) | [5,392](/filings/0001104659-25-120644.md) | [5,389](/filings/0001104659-26-027088.md) | [5,393](/filings/0001104659-26-107084.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,271,309 at 2033-09-12, from the cover of the [10-Q filed 2023-09-13](/filings/0001410578-23-002089.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.